Research

Hormonal

Intermittent administration of senolytic drugs (Dasatinib + Quercetin) or genetic clearance of senescent cells alleviates obesity-induced metabolic dysfunction, including insulin resistance and glucose intolerance, in obese mice.

This research suggests that targeting senescent cells (cells that have stopped dividing and secrete inflammatory factors) using specific drug combinations (like Dasatinib and Quercetin) or genetic methods can improve metabolic health in obesity. While not yet a standard human treatment, it highlights senolytics as a potential future therapy for obesity-related diabetes and inflammation.

GoodSupportsHIGH confidence
Here, we show that reducing senescent cell burden in obese mice, either by activating drug-inducible “suicide” genes driven by the p16Ink4a promoter or by treatment with senolytic agents, alleviates metabolic and adipose tissue dysfunction.
Allyson K. Palmer et al. · Aging Cell · 2019

Why this rating

High-quality preclinical evidence using multiple transgenic mouse models and senolytic drugs, though human data is limited to pilot trials mentioned in discussion.

Source

Targeting senescent cells alleviates obesity‐induced metabolic dysfunction

Allyson K. Palmer et al. · Aging Cell · 2019

DOI 10.1111/acel.12950

mechanism_onlyCited 662×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →